B
Bull
Bull · 25%HKPD
$1.53
Scenario price
$1.450
+0.096 (+6.62%)At close
Loading chart…
- High
- 1.600
- Open
- 1.420
- VWAP
- 1.47
- Volume
- 48.81K
- Mkt Cap
- —
- Low
- 1.360
- Amount
- 71.76K
- EV/EBITDA, TTM
- 0.00
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services.
AI analysis of Cellyan Biotechnology Co Ltd (HKPD)
SellGiven the current price of 1.45, the RSI at 25.446 indicates that the stock is oversold, but the significant year-to-date decline of 91.01% and negative earnings trends suggest that this is not a good buy right now. The main risk is the compliance warning from Nasdaq, which could further impact investor confidence and stock performance.
Valuation Metrics
The current forward P/E ratio for Cellyan Biotechnology Co Ltd (HKPD) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for HKPD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
7.007-17NASDAQ.COMCellyan Biotechnology Receives Nasdaq Compliance Extension
8.507-16seekingalphaCellyan Biotechnology Secures Nasdaq Compliance Extension
- 8.501-16seekingalpha
Cellyan Biotechnology (HKPD) Receives Nasdaq Warning for Non-Compliance with $1 Minimum Bid Price
7.001-16GlobenewswireCellyan Biotechnology Receives Nasdaq Notification for Share Price Below $1
- 9.012-17Globenewswire
HKPD Approves Major Capital Restructuring at 2025 Annual Meeting
HKPD FAQ — answered by Alphio AI
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services. It operates in the Healthcare sector.
Given the current price of 1.45, the RSI at 25.446 indicates that the stock is oversold, but the significant year-to-date decline of 91.01% and negative earnings trends suggest that this is not a good buy right now. The main risk is the compliance warning from Nasdaq, which could further impact investor confidence and stock performance.
Community
More ↗No posts yet
Sign up or log in to join the discussionRelated articles
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.